Jesús Martin-Garcia
Chief Executive Officer at GENEURO SA
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Elias Papatheodorou | M | 55 |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 9 years |
| Alexandre Grassin | M | 46 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 12 years |
| Claudio Nessi | M | 56 |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | - |
| Hervé Perron | M | 66 | 18 years | |
| Gordon Francis | M | 75 |
GeNeuro SA
 GeNeuro SA BiotechnologyHealth Technology Part of GeNeuro SA (Switzerland), the French company develops and manufactures therapeutic products. The private company is based in Lyon, France. | 9 years |
| Michel Dubois | M | 81 |
GeNeuro SA
GeNeuro SA BiotechnologyHealth Technology Part of GeNeuro SA (Switzerland), the French company develops and manufactures therapeutic products. The private company is based in Lyon, France. | 16 years |
| Giacomo di Nepi | M | 72 |
GeNeuro SA
GeNeuro SA BiotechnologyHealth Technology Part of GeNeuro SA (Switzerland), the French company develops and manufactures therapeutic products. The private company is based in Lyon, France. | 9 years |
| Philippe Archinard | M | 63 | 3 years | |
| Hedi Brahim | M | 43 | 4 years | |
| Cecilia Gonzalo | F | 49 |
Harvard Business School Health Industry Alumni Association
| - |
| Susan Alesina | F | 61 |
Harvard Business School Health Industry Alumni Association
| - |
| Kathryn Haviland | F | 48 |
Harvard Business School Health Industry Alumni Association
| - |
| Emily Levy | F | - |
Harvard Business School Health Industry Alumni Association
| - |
| Claude Bertrand | M | 61 |
Eclosion2 SA
 Eclosion2 SA Financial ConglomeratesFinance Eclosion2 SA provides financial services. | - |
| Nitin Thakor | M | - |
Harvard Business School Health Industry Alumni Association
| - |
| Claude Bagnoud | M | 60 |
Union des Associations Patronales Genevoises
| - |
| Philippe Wiesel | M | - |
Calliditas Therapeutics Suisse SA
Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | 14 years |
| Miguel Payró | M | 62 | 9 years | |
| Benoît Habert | M | 59 |
Eclosion2 SA
Eclosion2 SA Financial ConglomeratesFinance Eclosion2 SA provides financial services. | - |
| Todd Davis | M | 63 |
Harvard Business School Health Industry Alumni Association
| - |
| Anke Post | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| François Curtin | M | 60 | 11 years | |
| Christophe Guichard | M | 55 | - | |
| Mary C. Tanner | F | 73 | 5 years | |
| Eric Falcand | M | 63 | - | |
| Jean-Jacques Laborde | M | 79 | 6 years | |
| Hanna-Kaisa Borini | F | - | - | |
| Marc Bonneville | M | 65 | 5 years | |
| Catherine Moukheibir | F | 64 | 3 years | |
| Gilles Nobécourt | M | 67 | 12 years | |
| Renée Aguiar-Lucander | F | 62 | - | |
| Elmar Schnee | M | 65 | - | |
| Christophe Mérieux | M | - | - | |
| Alois B. Lang | M | 73 | - | |
| Robert Glanzman | M | 67 | 4 years | |
| Johan Luthman | M | 65 | - | |
| David Leppert | M | 66 | 4 years | |
| Jean-François Arrighi | M | 58 | 1 years | |
| Thomas Rückle | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 27 | 69.23% |
| France | 11 | 28.21% |
| United States | 6 | 15.38% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jesús Martin-Garcia
- Personal Network